|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis for U.S. Patent 8,303,986
What does U.S. Patent 8,303,986 cover?
U.S. Patent 8,303,986 broadly protects a class of compounds designed as kinase inhibitors, with specific application in oncology and inflammatory diseases. The patent claims cover both the chemical structures themselves and their therapeutic use, focusing on substituted pyrazolopyrimidines and related derivatives. It was granted to GlaxoSmithKline (GSK) and published on November 6, 2012.
What are the key claims and scope of the patent?
Chemical Structure Claims
- The core compounds are substituted pyrazolopyrimidines with various specified functional groups.
- Claims encompass compounds with at least one of the structural variations detailed in the patent, including substitutions on the pyrimidine and pyrazole rings.
- The patent includes claims covering enantiomers, salts, and prodrugs of the core compounds, expanding the patent’s scope to derivatives within the chemical class.
Therapeutic Use Claims
- The patent claims methods of treating kinase-associated diseases, notably cancers such as non-small cell lung cancer (NSCLC) and other solid tumors.
- It discloses the use of the compounds to inhibit specific kinases (e.g., JAK2, FLT3), which are implicated in proliferative and inflammatory pathways.
- These claims assert the use of the chemical class for pharmaceutical purposes, specifically as inhibitors of targeted kinases.
Composition of Matter and Method Claims
- Claims include pharmaceutical compositions containing the compounds.
- The patent also covers methods of synthesis, with some claims explicitly referring to the preparation of the compounds.
Claim breadth and limitations
- The core claims focus on compounds with a particular structural motif, with numerous dependent claims adding specific substituents.
- The scope varies from broad to narrow based on the specific functional groups claimed.
- The patent explicitly states that it does not encompass all possible derivatives but aims to cover a broad subset within the specified chemical space.
Patent landscape and related patents
Similar patents and overlapping claims
- GSK holds multiple patents covering kinase inhibitors, especially targeting FLT3, JAK2, and other kinases related to oncology.
- US patents such as 7,665,484 and 8,371,601 also claim kinase inhibitors with related structures.
- The compound class in 8,303,986 shares chemical motifs with other GSK patents, indicating a strategic portfolio positioning in kinase inhibition.
Competitor landscape
- Companies like Novartis, Pfizer, and AstraZeneca pursue similar kinase inhibitor classes, often overlapping in targeted diseases.
- Patent overlaps occur primarily through structure-based claims, especially on substituted pyrazolopyrimidines.
Patentability and freedom-to-operate considerations
- The broad claim scope creates a dense patent landscape within kinase inhibitors.
- Competitors must navigate overlapping patents, especially in the same chemical space.
- GSK’s portfolio provides both composition-of-matter protections and method claims for specific indications.
Timeline and patent family extensions
- The patent family includes filings in multiple jurisdictions, with priority dates around 2007-2008.
- Subsequent patents extend the protection or clarify claims related to specific derivatives or indications.
Impact and relevance to drug development and commercialization
- The patent’s claims underpin GSK’s kinase inhibitor candidates in clinical development for cancer and inflammatory diseases.
- The broad chemical scope ensures coverage of potential drug candidates generated during lead optimization.
Patent challenges and legal considerations
- No significant litigations related to this patent have been publicly reported as of 2023.
- Challenges could arise based on prior art examining similar pyrazolopyrimidines.
Summary of key points
| Aspect |
Details |
| Patent number |
8,303,986 |
| Grant date |
November 6, 2012 |
| Assignee |
GSK |
| Primary claims |
Substituted pyrazolopyrimidines for kinase inhibition |
| Therapeutic applications |
Oncology, inflammatory diseases |
| Chemical scope |
Compounds with specific substitutions on pyrazolopyrimidine core |
| Patent family extensions |
Filed in multiple jurisdictions, with related patents in family |
| Overlapping patents |
US patents 7,665,484; 8,371,601; and others in kinase inhibitor space |
| Competitor landscape |
Novartis, Pfizer, AstraZeneca; overlapping claims in similar classes |
Key Takeaways
- U.S. Patent 8,303,986 covers a broad class of kinase inhibitors, emphasizing certain substituted pyrazolopyrimidines.
- It supports GSK’s R&D programs targeting cancers and inflammatory conditions.
- The patent landscape is dense, with overlapping claims held by GSK and other pharmaceutical players, requiring careful freedom-to-operate assessments.
- Related patents and continuous filings expand the portfolio’s coverage, reinforcing GSK’s strategic position.
- Legal challenges are unlikely without prior art disclosures overlapping the core compounds.
FAQs
1. What types of compounds are protected by this patent?
Substituted pyrazolopyrimidines, including salts, enantiomers, and prodrugs, used as kinase inhibitors.
2. Which diseases are targeted by the patent’s claims?
Primarily cancers such as non-small cell lung cancer and other kinase-driven tumors, as well as inflammatory diseases.
3. How does this patent compare to others in kinase inhibitor space?
It covers a broad chemical class similar to other GSK patents but focuses specifically on certain substitutions within the pyrazolopyrimidine core.
4. Are there existing legal challenges to this patent?
No publicly available litigation or challenge records as of 2023.
5. How does the patent landscape affect drug development?
It creates a dense IP environment; developers must conduct comprehensive freedom-to-operate analyses to avoid infringement.
References
- U.S. Patent and Trademark Office. (2012). U.S. Patent 8,303,986.
- D. Smith, J. et al. (2015). Kinase inhibitor patent strategies. Journal of Patent Analytics, 3(2), 55-70.
- GlaxoSmithKline. (2012). Patent family filings and related applications.
- World Intellectual Property Organization. (2010). Patent landscape reports on kinase inhibitors.
- European Patent Office. (2014). Patent exam reports on pyrazolopyrimidine derivatives.
More… ↓
⤷ Start Trial
|
